RESUMEN
We report a rapidly progressive and fatal CD8 T-cell-mediated cerebellitis after ipilimumab (cytotoxic T-lymphocyte-associated protein 4 inhibitor) for small cell lung cancer. Clinical features and histopathology were consistent with an accelerated form of paraneoplastic cerebellar degeneration. A patchy CD8 T-cell infiltrate spatially corresponded to areas of Purkinje cell loss, with occasional CD8 polarisation towards Purkinje cells. CD20-positive B cells were sparse. CD8 T-cell-mediated cerebellitis after immune checkpoint inhibitor treatment may recapitulate the early stages of paraneoplastic cerebellar degeneration.
Asunto(s)
Linfocitos T CD8-positivos/inmunología , Inhibidores de Puntos de Control Inmunológico/efectos adversos , Ipilimumab/efectos adversos , Neoplasias Pulmonares/tratamiento farmacológico , Degeneración Cerebelosa Paraneoplásica/inducido químicamente , Células de Purkinje/inmunología , Carcinoma Pulmonar de Células Pequeñas/tratamiento farmacológico , Humanos , Inhibidores de Puntos de Control Inmunológico/administración & dosificación , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Ipilimumab/administración & dosificación , Ipilimumab/uso terapéutico , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Degeneración Cerebelosa Paraneoplásica/inmunología , Células de Purkinje/efectos de los fármacos , Carcinoma Pulmonar de Células Pequeñas/inmunología , Carcinoma Pulmonar de Células Pequeñas/patologíaRESUMEN
OBJECTIVE: To describe the identification of regulator of G-protein signaling 8 (RGS8) as an autoantibody target in patients with cerebellar syndrome associated with lymphoma. METHODS: Sera of 4 patients with a very similar unclassified reactivity against cerebellar Purkinje cells were used in antigen identification experiments. Immunoprecipitations with cerebellar lysates followed by mass spectrometry identified the autoantigen, which was verified by recombinant immunofluorescence assay, immunoblot, and ELISA with the recombinant protein. RESULTS: The sera and CSF of 4 patients stained the Purkinje cells and molecular layer of the cerebellum. RGS8 was identified as the target antigen in all 4 sera. In a neutralization experiment, recombinant human RGS8 was able to neutralize the autoantibodies' tissue reaction. Patient sera and CSF showed a specific reactivity against recombinant RGS8 in ELISA and immunoblot, whereas no such reactivity was detectable in the controls. Clinical data were available for 2 of the 4 patients, remarkably both presented with cerebellar syndrome accompanied by B-cell lymphoma of the stomach (patient 1, 53 years) or Hodgkin lymphoma (patient 2, 74 years). CONCLUSION: Our results indicate that autoantibodies against the intracellular Purkinje cell protein RGS8 represent new markers for paraneoplastic cerebellar syndrome associated with lymphoma. CLASSIFICATION OF EVIDENCE: This study provided Class IV evidence that autoantibodies against the intracellular Purkinje cell protein RGS8 are associated with paraneoplastic cerebellar syndrome in lymphoma.
Asunto(s)
Autoanticuerpos/inmunología , Degeneración Cerebelosa Paraneoplásica/inmunología , Células de Purkinje/inmunología , Proteínas RGS/metabolismo , Anciano , Animales , Cerebelo/patología , Femenino , Células HEK293 , Haplorrinos , Voluntarios Sanos , Humanos , Linfoma/inmunología , Masculino , Persona de Mediana Edad , Degeneración Cerebelosa Paraneoplásica/complicaciones , RatasRESUMEN
OBJECTIVE: Identify the subcellular location and potential binding partners of two cerebellar degeneration-related proteins, CDR2L and CDR2, associated with anti-Yo-mediated paraneoplastic cerebellar degeneration. METHODS: Cancer cells, rat Purkinje neuron cultures, and human cerebellar sections were exposed to cerebrospinal fluid and serum from patients with paraneoplastic cerebellar degeneration with Yo antibodies and with several antibodies against CDR2L and CDR2. We used mass spectrometry-based proteomics, super-resolution microscopy, proximity ligation assay, and co-immunoprecipitation to verify the antibodies and to identify potential binding partners. RESULTS: We confirmed the CDR2L specificity of Yo antibodies by mass spectrometry-based proteomics and found that CDR2L localized to the cytoplasm and CDR2 to the nucleus. CDR2L co-localized with the 40S ribosomal protein S6, while CDR2 co-localized with the nuclear speckle proteins SON, eukaryotic initiation factor 4A-III, and serine/arginine-rich splicing factor 2. INTERPRETATION: We showed that Yo antibodies specifically bind to CDR2L in Purkinje neurons of PCD patients where they potentially interfere with the function of the ribosomal machinery resulting in disrupted mRNA translation and/or protein synthesis. Our findings demonstrating that CDR2L interacts with ribosomal proteins and CDR2 with nuclear speckle proteins is an important step toward understanding PCD pathogenesis.
Asunto(s)
Autoanticuerpos , Autoantígenos , Núcleo Celular , Citoplasma , Proteínas del Tejido Nervioso , Degeneración Cerebelosa Paraneoplásica , Biosíntesis de Proteínas , Células de Purkinje , Animales , Autoanticuerpos/inmunología , Autoanticuerpos/metabolismo , Autoantígenos/inmunología , Autoantígenos/metabolismo , Línea Celular Tumoral , Núcleo Celular/inmunología , Núcleo Celular/metabolismo , Citoplasma/inmunología , Citoplasma/metabolismo , Humanos , Inmunoprecipitación , Espectrometría de Masas , Proteínas del Tejido Nervioso/inmunología , Proteínas del Tejido Nervioso/metabolismo , Degeneración Cerebelosa Paraneoplásica/inmunología , Degeneración Cerebelosa Paraneoplásica/metabolismo , Biosíntesis de Proteínas/fisiología , Proteómica , Células de Purkinje/inmunología , Células de Purkinje/metabolismo , RatasRESUMEN
BACKGROUND: Paraneoplastic cerebellar degeneration (PCD) is a devastating paraneoplastic syndrome that occasionally occurs in patients with Hodgkin lymphoma (HL). Anti-Ma2 is a well-characterized onconeuronal antibody and one of the causes of PCD. There has been only one previous report of anti-Ma2-associated paraneoplastic syndrome as a complication of HL. Here we present a rare case of anti-Ma2-associated PCD in a patient with nodular lymphocyte-predominant HL (NLPHL). CASE PRESENTATION: A 77-year-old man with a 3-month history of gait instability and a 2-month history of oscillopsia was referred to our hospital for further investigation. On examination, his cognition was normal. He had nystagmus in all directions of gaze; specifically, he had horizontal and rotatory nystagmus in the primary position, downbeat nystagmus after right, left, and up gaze, and upbeat nystagmus after down gaze. Although his limb ataxia was mild, his trunk ataxia was so pronounced that he was unable to walk without support. We strongly suspected paraneoplastic syndrome and tested for neuronal autoantibodies. The anti-Ma2 antibody was strongly positive in the blood and cerebrospinal fluid but other antineuronal autoantibodies were negative. Computed tomography showed an enlarged lymph node in the right axilla but no masses. Biopsy confirmed a diagnosis of NLPHL. The NLPHL cells stained with anti-Ma-2 antibody in the cytoplasm, suggesting these abnormal cells contained protein that was cross-reactive with Ma-2. CONCLUSIONS: To the best of our knowledge, this is the first case of anti-Ma2-associated PCD in a patient with NLPHL that was confirmed using immunostaining of the lymph node tissue with anti-Ma2 antibody. Our case confirms an association between anti-Ma2-associated PCD and NLPHL.
Asunto(s)
Antígenos de Neoplasias/inmunología , Enfermedad de Hodgkin/complicaciones , Proteínas del Tejido Nervioso/inmunología , Degeneración Cerebelosa Paraneoplásica/etiología , Degeneración Cerebelosa Paraneoplásica/inmunología , Anciano , Autoanticuerpos/sangre , Autoanticuerpos/inmunología , Autoantígenos/inmunología , Enfermedad de Hodgkin/inmunología , Humanos , Masculino , Degeneración Cerebelosa Paraneoplásica/diagnóstico , Tomografía Computarizada por Rayos XRESUMEN
Paraneoplastic cerebellar degeneration (PCD) is a rare immune-mediated disease that develops mostly in the setting of neoplasia and offers a unique prospect to explore the interplay between tumor immunity and autoimmunity. In PCD, the deleterious adaptive immune response targets self-antigens aberrantly expressed by tumor cells, mostly gynecological cancers, and physiologically expressed by the Purkinje neurons of the cerebellum. Highly specific anti-neuronal antibodies in the serum and cerebrospinal fluid represent key diagnostic biomarkers of PCD. Some anti-neuronal antibodies such as anti-Yo autoantibodies (recognizing the CDR2/CDR2L proteins) are only associated with PCD. Other anti-neuronal antibodies, such as anti-Hu, anti-Ri, and anti-Ma2, are detected in patients with PCD or other types of paraneoplastic neurological manifestations. Importantly, these autoantibodies cannot transfer disease and evidence for a pathogenic role of autoreactive T cells is accumulating. However, the precise mechanisms responsible for disruption of self-tolerance to neuronal self-antigens in the cancer setting and the pathways involved in pathogenesis within the cerebellum remain to be fully deciphered. Although the occurrence of PCD is rare, the risk for such severe complication may increase with wider use of cancer immunotherapy, notably immune checkpoint blockade. Here, we review recent literature pertaining to the pathophysiology of PCD and propose an immune scheme underlying this disabling disease. Additionally, based on observations from patients' samples and on the pre-clinical model we recently developed, we discuss potential therapeutic strategies that could blunt this cerebellum-specific autoimmune disease.
Asunto(s)
Antígenos de Neoplasias/inmunología , Autoanticuerpos/inmunología , Autoinmunidad , Cerebelo/inmunología , Neoplasias/inmunología , Degeneración Cerebelosa Paraneoplásica/inmunología , Animales , Autoantígenos/inmunología , Autoantígenos/metabolismo , Cerebelo/metabolismo , Cerebelo/patología , Humanos , Inmunoterapia/efectos adversos , Neoplasias/metabolismo , Neoplasias/patología , Neoplasias/terapia , Proteínas del Tejido Nervioso/inmunología , Proteínas del Tejido Nervioso/metabolismo , Degeneración Cerebelosa Paraneoplásica/metabolismo , Degeneración Cerebelosa Paraneoplásica/patología , Células de Purkinje/inmunología , Células de Purkinje/metabolismo , Células de Purkinje/patología , Factores de Riesgo , Linfocitos T/inmunología , Linfocitos T/metabolismoRESUMEN
OBJECTIVE: To describe the main syndrome and clinical course in a large cohort of patients with anti-Ri-associated paraneoplastic neurologic syndrome (Ri-PNS). METHODS: Twenty-year retrospective nationwide study and systematic review of the literature. RESULTS: Thirty-six patients with complete clinical information were identified (median age 66 years, range: 47-87 years). In this French cohort, the majority were women (78%). At onset, 4 main patterns were observed: cerebellar syndrome (39%), isolated tremor (24%), oculomotor disturbances (17%), and other symptoms (19%). Course was multistep for 78% of cases. At the time the disease reached the plateau phase (median 12 weeks, range: 1-64 weeks; 28% >3 months), 24 (67%) showed an overt cerebellar syndrome, which was isolated in 3 patients, and was most frequently (21/24 cases) part of a multisystem neurologic disease. Patients manifested a variety of movement disorders, including myoclonus (33%), dystonia (17%), either cervical or oromandibular, and parkinsonism (17%). Most patients had cancer (92%), mainly breast cancer (n = 22). Misdiagnoses concerned 22% of patients (n = 8) and included atypical parkinsonism (n = 2), MS (n = 2), Bickerstaff encephalitis (n = 1), hyperekplexia (n = 1), vestibular neuritis (n = 1), and functional neurologic disorder (n = 1). Survival at 12 months was 73% (95% CI [0.54-0.85]), at 24 months 62% (95% CI [0.41-0.78]), and at 36 months 47% (95% CI [0.25-0.65]). There was no major clinical difference between cases retrieved from the systematic review of the literature (n = 55) and the French cohort. CONCLUSIONS: Ri-PNS is a multisystem neurologic syndrome with prominent cerebellum/brainstem involvement. Opsoclonus-myoclonus is less common than expected, and the disorder can mimic neurodegenerative diseases.
Asunto(s)
Trastornos del Movimiento , Proteínas del Tejido Nervioso/inmunología , Síndromes Paraneoplásicos del Sistema Nervioso , Proteínas de Unión al ARN/inmunología , Anciano , Anciano de 80 o más Años , Femenino , Francia , Humanos , Masculino , Persona de Mediana Edad , Trastornos del Movimiento/diagnóstico , Trastornos del Movimiento/epidemiología , Trastornos del Movimiento/etiología , Trastornos del Movimiento/inmunología , Antígeno Ventral Neuro-Oncológico , Degeneración Cerebelosa Paraneoplásica/diagnóstico , Degeneración Cerebelosa Paraneoplásica/epidemiología , Degeneración Cerebelosa Paraneoplásica/inmunología , Síndromes Paraneoplásicos del Sistema Nervioso/complicaciones , Síndromes Paraneoplásicos del Sistema Nervioso/diagnóstico , Síndromes Paraneoplásicos del Sistema Nervioso/epidemiología , Síndromes Paraneoplásicos del Sistema Nervioso/inmunología , Estudios RetrospectivosRESUMEN
BACKGROUND: The epidemiology of paraneoplastic neurological syndromes (PNS) remains to be defined. We present here the first population-based incidence study and report the clinical spectrum and antibody profile of PNS in a large area in Northeastern Italy. METHODS: We performed a 9-year (2009-2017) population-based epidemiological study of PNS in the provinces of Udine, Pordenone and Gorizia, in the Friuli-Venezia Giulia region (983,190 people as of January 1, 2017). PNS diagnosis and subgroups were defined by the 2004 diagnostic criteria. Age- and sex-adjusted incidence rates were calculated. RESULTS: We identified 89 patients with a diagnosis of definite PNS. Median age was 68 years (range 26-90), 52% were female. The incidence of PNS was 0.89/100,000 person-years. PNS incidence rates increased over time from 0.62/100,000 person-years (2009-2011), 0.81/100,000 person-years (2012-2014) to 1.22/100,000 person-years (2015-2017). The prevalence of PNS was 4.37 per 100,000. Most common PNS were limbic encephalitis (31%), cerebellar degeneration (28%) and encephalomyelitis (20%). Among antibody (Ab)-positive cases, most frequent specificities included: Yo (30%), Hu (26%), and Ma2 (22%), while the most frequent associated tumors were lung (17%) and breast cancer (16%), followed by lymphoma (12%). PNS developed in 1 in every 334 cancers in our region. Statistically significant associations were observed between cancer type and Ab-specificity (P < 0.001), and between neurological syndrome and Ab-specificity (P < 0.001). CONCLUSIONS: This first population-based study found an incidence of PNS that approximates 1/100,000 person-years and a prevalence of 4/100,000. Moreover, the incidence of PNS is increasing over time, probably due to increased awareness and improved detection techniques.
Asunto(s)
Encefalomielitis/epidemiología , Neoplasias/epidemiología , Síndromes Paraneoplásicos del Sistema Nervioso/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Encefalomielitis/inmunología , Femenino , Humanos , Incidencia , Italia/epidemiología , Encefalitis Límbica/epidemiología , Encefalitis Límbica/inmunología , Masculino , Persona de Mediana Edad , Degeneración Cerebelosa Paraneoplásica/epidemiología , Degeneración Cerebelosa Paraneoplásica/inmunología , Síndromes Paraneoplásicos del Sistema Nervioso/inmunología , PrevalenciaRESUMEN
Paraneoplastic neurologic degeneration (PND) is characterized by acute and subacute onset neurological syndrome associated with active or with subclinical cancer. It is rare but early diagnosis can improve the neurological and carcinological prognosis. Among the PNDs it is possible to distinguish subacute cerebellar degeneration often associated with gynecological or breast cancer. We report the case of a 50-year old female patient on follow-up for ovarian adenocarcinoma treated with surgery and whose recurrence was detected due to anti-Yo antibody-positive subacute cerebellar degeneration.
Asunto(s)
Adenocarcinoma/diagnóstico , Neoplasias Ováricas/diagnóstico , Degeneración Cerebelosa Paraneoplásica/diagnóstico , Adenocarcinoma/patología , Femenino , Humanos , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Proteínas del Tejido Nervioso/inmunología , Neoplasias Ováricas/patología , Degeneración Cerebelosa Paraneoplásica/inmunología , PronósticoRESUMEN
Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disease of the neuromuscular junction caused by autoantibodies binding to P/Q-type voltage-gated calcium channels. Breakdown of the blood-brain barrier and diffusion of cerebellar granule/Purkinje cell-reactive autoantibodies into the CNS are critical for the pathogenesis of paraneoplastic cerebellar degeneration (PCD) with Lambert-Eaton myasthenic syndrome. We recently found evidence that glucose-regulated protein 78 (GRP78) autoantibodies in the plasma of patients with neuromyelitis optica promote the CNS access of AQP4 autoantibodies. In the present study, we investigated whether the GRP78 autoantibodies in PCD-LEMS IgG boost the brain uptake of cerebellar cell-reactive antibodies across the blood-brain barrier and facilitate cerebellar dysfunction. We first evaluated the effects of purified IgG from PCD-LEMS or PCD patients on the blood-brain barrier function in human brain microvascular endothelial cells using a high content imaging system with nuclear factor κB p65 and intracellular adhesion molecule 1 (ICAM1) immunostaining. Next, we identified GRP78 autoantibodies causing blood-brain barrier permeability in PCD-LEMS IgG by co-immunoprecipitation and the living cell-based antibody binding assays. Exposure of brain microvascular endothelial cells to IgG from PCD-LEMS patients induced nuclear factor κB p65 nuclear translocation, ICAM1 upregulation, reduced claudin-5 expression, increased permeability and increased autocrine IL-1ß and IL-8 secretion; the IgG from patients with Lambert-Eaton myasthenic syndrome did not have these effects. We detected GRP78 autoantibodies in the IgG of LEMS-PCD (83.3%, n = 18), but observed fewer in patients with LEMS (6.6%, n = 15) and none were observed in the control subjects (n = 8). The depletion of GRP78 autoantibodies reduced the biological effect of LEMS-PCD IgG on brain microvascular endothelial cells. These findings suggest that GRP78 autoantibodies play a role beyond neuromyelitis optica and that they have direct implications in the phenotypic differences between PCD-LEMS and LEMS.
Asunto(s)
Autoanticuerpos/inmunología , Barrera Hematoencefálica/patología , Proteínas de Choque Térmico/inmunología , Síndrome Miasténico de Lambert-Eaton/inmunología , Degeneración Cerebelosa Paraneoplásica/inmunología , Anciano , Anciano de 80 o más Años , Autoantígenos/inmunología , Chaperón BiP del Retículo Endoplásmico , Femenino , Humanos , Síndrome Miasténico de Lambert-Eaton/patología , Neoplasias Pulmonares/inmunología , Masculino , Persona de Mediana Edad , Degeneración Cerebelosa Paraneoplásica/patología , Carcinoma Pulmonar de Células Pequeñas/inmunologíaAsunto(s)
Neoplasias de las Trompas Uterinas/complicaciones , Degeneración Cerebelosa Paraneoplásica/complicaciones , Anciano de 80 o más Años , Autoanticuerpos/análisis , Neoplasias de las Trompas Uterinas/diagnóstico , Femenino , Humanos , Degeneración Cerebelosa Paraneoplásica/diagnóstico , Degeneración Cerebelosa Paraneoplásica/inmunología , Células de Purkinje/inmunologíaRESUMEN
Paraneoplastic neurological disorders result from an autoimmune response against neural self-antigens that are ectopically expressed in neoplastic cells. In paraneoplastic disorders associated to autoantibodies against intracellular proteins, such as paraneoplastic cerebellar degeneration (PCD), current data point to a major role of cell-mediated immunity. In an animal model, in which a neo-self-antigen was expressed in both Purkinje neurons and implanted breast tumor cells, immune checkpoint blockade led to complete tumor control at the expense of cerebellum infiltration by T cells and Purkinje neuron loss, thereby mimicking PCD. Here, we identify 2 potential therapeutic targets expressed by cerebellum-infiltrating T cells in this model, namely α4 integrin and IFN-γ. Mice with PCD were treated with anti-α4 integrin antibodies or neutralizing anti-IFN-γ antibodies at the onset of neurological signs. Although blocking α4 integrin had little or no impact on disease development, treatment using the anti-IFN-γ antibody led to almost complete protection from PCD. These findings strongly suggest that the production of IFN-γ by cerebellum-invading T cells plays a major role in Purkinje neuron death. Our successful preclinical use of neutralizing anti-IFN-γ antibody for the treatment of PCD offers a potentially new therapeutic opportunity for cancer patients at the onset of paraneoplastic neurological disorders.
Asunto(s)
Interferón gamma/antagonistas & inhibidores , Neoplasias Mamarias Experimentales/complicaciones , Degeneración Cerebelosa Paraneoplásica/tratamiento farmacológico , Células de Purkinje/patología , Linfocitos T/efectos de los fármacos , Animales , Antígenos de Neoplasias/inmunología , Autoanticuerpos/inmunología , Autoantígenos/inmunología , Línea Celular Tumoral/trasplante , Femenino , Integrina alfa4/antagonistas & inhibidores , Integrina alfa4/inmunología , Integrina alfa4/metabolismo , Interferón gamma/inmunología , Interferón gamma/metabolismo , Neoplasias Mamarias Experimentales/inmunología , Ratones , Ratones Noqueados , Degeneración Cerebelosa Paraneoplásica/inmunología , Degeneración Cerebelosa Paraneoplásica/patología , Células de Purkinje/inmunología , Células de Purkinje/metabolismo , Linfocitos T/inmunología , Linfocitos T/metabolismoRESUMEN
AIM: Neurodegeneration is associated with dysfunction of calcium buffering capacity and thereby sustained cellular and mitochondrial calcium overload. Paraneoplastic cerebellar degeneration (PCD), characterized by progressive Purkinje neurone degeneration following paraneoplastic Yo antibody internalization and binding to cerebellar degeneration-related protein CDR2 and CDR2L, has been linked to intracellular calcium homeostasis imbalance due to calbindin D28k malfunction. Therefore, we hypothesized that Yo antibody internalization affects not only calbindin calcium binding capacity, but also calcium-sensitive mitochondrial-associated signalling, causing mitochondrial calcium overload and thereby Purkinje neurone death. METHODS: Immunohistochemically, we evaluated cerebellar organotypic slice cultures of rat brains after inducing PCD through the application of Yo antibody-positive PCD patient sera or purified antibodies against CDR2 and CDR2L how pharmacologically biased mitochondrial signalling affected PCD pathology. RESULTS: We found that Yo antibody internalization into Purkinje neurons caused depletion of Purkinje neurone calbindin-immunoreactivity, cannabinoid 1 receptor over-activation and alterations in the actions of the mitochondria permeability transition pore (MPTP), voltage-dependent anion channels, reactive oxygen species (ROS) and Na+ /Ca2+ exchangers (NCX). The pathological mechanisms caused by Yo antibody binding to CDR2 or CDR2L differed between the two targets. Yo-CDR2 binding did not alter the mitochondrial calcium retention capacity, cyclophilin D-independent opening of MPTP or activity of NCX. CONCLUSION: These findings suggest that minimizing intracellular calcium overload toxicity either directly with cyclosporin-A or indirectly with cannabidiol or the ROS scavenger butylated hydroxytoluene promotes mitochondrial calcium homeostasis and may therefore be used as future neuroprotective therapy for PCD patients.
Asunto(s)
Calcio/metabolismo , Mitocondrias/patología , Degeneración Cerebelosa Paraneoplásica/patología , Células de Purkinje/patología , Animales , Autoanticuerpos/inmunología , Enfermedades Cerebelosas/patología , Cerebelo/patología , Humanos , Mitocondrias/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Degeneración Cerebelosa Paraneoplásica/inmunología , Células de Purkinje/metabolismo , RatasRESUMEN
To describe autoantibodies (Abs) against tripartite motif-containing (TRIM) protein 9 and 67 in two patients with paraneoplastic cerebellar degeneration (PCD) associated with lung adenocarcinoma. Abs were characterized using immunohistochemistry, Western blotting, cultures of murine cortical, and hippocampal neurons, immunoprecipitation, mass spectrometry, knockout mice for Trim9 and 67, and cell-based assay. Control samples included sera from 63 patients with small cell lung cancer without any paraneoplastic neurological syndrome, 36 patients with lung adenocarcinoma and PNS, CSF from 100 patients with autoimmune encephalitis, and CSF from 165 patients with neurodegenerative diseases. We found Abs targeting TRIM9 and TRIM67 at high concentration in the serum and the cerebrospinal fluid (CSF) of a 78-year-old woman and a 65-year-old man. Both developed subacute severe cerebellar ataxia. Brain magnetic resonance imaging found no abnormality and no cerebellar atrophy. Both had CSF inflammation with mild pleiocytosis and a few oligoclonal bands. We identified a pulmonary adenocarcinoma, confirming the paraneoplastic neurological syndrome in both patients. They received immunomodulatory and cancer treatments without improvement of cerebellar ataxia, even though both were in remission of their cancer (for more than 10 years in one patient). Anti-TRIM9 and anti-TRIM67 Abs were specific to these two patients. All control serum and CSF samples tested were negative for anti-TRIM9 and 67. Anti-TRIM9 and anti-TRIM67 Abs appeared to be specific biomarkers of PCD and should be added to the panel of antigens tested when this is suspected.
Asunto(s)
Autoanticuerpos/sangre , Autoanticuerpos/líquido cefalorraquídeo , Encéfalo/inmunología , Proteínas del Citoesqueleto/inmunología , Proteínas del Tejido Nervioso/inmunología , Degeneración Cerebelosa Paraneoplásica/inmunología , Proteínas de Motivos Tripartitos/inmunología , Ubiquitina-Proteína Ligasas/inmunología , Adenocarcinoma/inmunología , Anciano , Animales , Biomarcadores/sangre , Biomarcadores/líquido cefalorraquídeo , Proteínas Portadoras/genética , Proteínas Portadoras/metabolismo , Células Cultivadas , Encefalitis/inmunología , Femenino , Enfermedad de Hashimoto/inmunología , Humanos , Péptidos y Proteínas de Señalización Intracelular/genética , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Neoplasias Pulmonares/inmunología , Masculino , Ratones Endogámicos C57BL , Ratones Noqueados , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/metabolismo , Neuronas/inmunología , Degeneración Cerebelosa Paraneoplásica/diagnóstico por imagen , Degeneración Cerebelosa Paraneoplásica/terapia , Carcinoma Pulmonar de Células Pequeñas/inmunologíaRESUMEN
BACKGROUND: Paraneoplastic neurological syndromes are rare conditions where an autoimmune reaction against the nervous system appears in patients suffering from a tumour, but not linked to the spreading of the tumour. A break in the immune tolerance is thought to be the trigger. METHODS: The transcriptomic profile of 12 ovarian tumours (OT) from patients suffering from paraneoplastic cerebellar degeneration (PCD) linked to anti-Yo antibodies (anti-Yo PCD OT) was compared with 733 ovarian tumours (OT control) from different public databases using linear model analysis. RESULTS: A prominent significant transcriptomic over-representation of CD8+ and Treg cells was found in anti-Yo PCD OT, as compared to the OT control. However, the overall degree of immune cell infiltration was similar, according to the ESTIMATE immune score. We also found an under-representation of M2 macrophages in anti-Yo PCD OT. Furthermore, the differentially expressed genes were enriched for AIRE-related genes, a well-known transcription factor associated with a broad range of autoimmune diseases. Finally, we found that the differentially expressed genes were correlated to the transcriptomic profiling of the cerebellar structures. CONCLUSIONS: Our data pinpointed the enrichment of acquired immune response, particularly high density of CD8+ lymphocytes, and high-level expression of CDR-related antigens in anti-Yo PCD OT.
Asunto(s)
Proteínas del Tejido Nervioso/genética , Neoplasias Ováricas/genética , Degeneración Cerebelosa Paraneoplásica/genética , Transcriptoma/genética , Anciano , Anciano de 80 o más Años , Linfocitos T CD8-positivos/inmunología , Femenino , Humanos , Análisis por Micromatrices , Persona de Mediana Edad , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/inmunología , Proteínas del Tejido Nervioso/inmunología , Neoplasias Ováricas/complicaciones , Neoplasias Ováricas/inmunología , Neoplasias Ováricas/patología , Degeneración Cerebelosa Paraneoplásica/complicaciones , Degeneración Cerebelosa Paraneoplásica/inmunología , Degeneración Cerebelosa Paraneoplásica/patología , Linfocitos T Reguladores/inmunología , Factores de Transcripción/genética , Factores de Transcripción/inmunología , Transcriptoma/inmunología , Proteína AIRERESUMEN
Paraneoplastic cerebellar degenerations with anti-Yo antibodies (Yo-PCD) are rare syndromes caused by an auto-immune response against neuronal antigens (Ags) expressed by tumor cells. However, the mechanisms responsible for such immune tolerance breakdown are unknown. We characterized 26 ovarian carcinomas associated with Yo-PCD for their tumor immune contexture and genetic status of the 2 onconeural Yo-Ags, CDR2 and CDR2L. Yo-PCD tumors differed from the 116 control tumors by more abundant T and B cells infiltration occasionally organized in tertiary lymphoid structures harboring CDR2L protein deposits. Immune cells are mainly in the vicinity of apoptotic tumor cells, revealing tumor immune attack. Moreover, contrary to un-selected ovarian carcinomas, 65% of our Yo-PCD tumors presented at least one somatic mutation in Yo-Ags, with a predominance of missense mutations. Recurrent gains of the CDR2L gene with tumor protein overexpression were also present in 59% of Yo-PCD patients. Overall, each Yo-PCD ovarian carcinomas carried at least one genetic alteration of Yo-Ags. These data demonstrate an association between massive infiltration of Yo-PCD tumors by activated immune effector cells and recurrent gains and/or mutations in autoantigen-encoding genes, suggesting that genetic alterations in tumor cells trigger immune tolerance breakdown and initiation of the auto-immune disease.
Asunto(s)
Autoantígenos/genética , Proteínas del Tejido Nervioso/genética , Neoplasias Ováricas/genética , Neoplasias Ováricas/inmunología , Degeneración Cerebelosa Paraneoplásica/genética , Degeneración Cerebelosa Paraneoplásica/inmunología , Linfocitos B/inmunología , Linfocitos B/patología , Carcinoma/genética , Carcinoma/inmunología , Carcinoma/patología , Estudios de Cohortes , Femenino , Expresión Génica , Humanos , Inmunoglobulina G/metabolismo , Persona de Mediana Edad , Mutación , Clasificación del Tumor , Neoplasias Ováricas/patología , Degeneración Cerebelosa Paraneoplásica/patología , Linfocitos T/inmunología , Linfocitos T/patologíaRESUMEN
The paraneoplastic cerebellar syndrome presents as severe neuroimmunological disease associated with malignancies. Antibodies against antigens expressed by tumor cells cross-react with proteins of cerebellar Purkinje cells leading to neuroinflammation and neuronal loss. These antineuronal antibodies are preferentially investigated by serological analyses while examination of the cerebrospinal fluid is only performed infrequently. We retrospectively investigated 12 patients with antineuronal antibodies against Purkinje cells with a special focus on cerebrospinal fluid. Our results confirm a subacute disease with a severe cerebellar syndrome in 10 female patients due to anti-Yo antibodies associated mostly with gynecological malignancies. While standard cerebrospinal fluid parameters infrequently revealed pathological results, all patients presented oligoclonal bands indicating intrathecal IgG synthesis. Analyses of anti-Yo antibodies in cerebrospinal fluid by calculating the antibody specific index revealed intrathecal synthesis of anti-Yo antibodies in these patients. In analogy to anti-Yo syndrome, an intrathecal production of anti-Tr antibodies in one patient who presented with a paraneoplastic cerebellar syndrome was detected. In an additional patient, anti-Purkinje cell antibodies of unknown origin in the cerebrospinal fluid but not in serum were determined suggesting an isolated immune reaction within the central nervous system (CNS) and underlining the importance of investigating the cerebrospinal fluid. In conclusion, patients with a cerebellar syndrome display a distinct immune reaction within the cerebrospinal fluid including intrathecal synthesis of disease-specific antibodies. We emphasize the importance of a thorough immunological work up including investigations of both serum and cerebrospinal fluid.
Asunto(s)
Autoanticuerpos/metabolismo , Proteínas del Tejido Nervioso/inmunología , Degeneración Cerebelosa Paraneoplásica/inmunología , Degeneración Cerebelosa Paraneoplásica/patología , Células de Purkinje/metabolismo , Receptores de Superficie Celular/inmunología , Adulto , Anciano , Femenino , Humanos , Imagen por Resonancia Magnética , Persona de Mediana Edad , Degeneración Cerebelosa Paraneoplásica/diagnóstico por imagen , Degeneración Cerebelosa Paraneoplásica/metabolismo , Células de Purkinje/inmunología , Estudios RetrospectivosAsunto(s)
Anticuerpos/metabolismo , Encéfalo/metabolismo , Neoplasias de las Trompas Uterinas/inmunología , Degeneración Cerebelosa Paraneoplásica/inmunología , Proteínas/inmunología , Células de Purkinje/patología , Huso Acromático/metabolismo , Apoptosis , Autoantígenos/inmunología , Encéfalo/patología , Femenino , Células HeLa , Humanos , Mitosis , Proteínas del Tejido Nervioso/inmunología , PosmenopausiaAsunto(s)
Autoanticuerpos/sangre , Proteínas del Tejido Nervioso/inmunología , Degeneración Cerebelosa Paraneoplásica/inmunología , Factores de Transcripción/inmunología , Anciano de 80 o más Años , Femenino , Humanos , Linfoma de Células B Grandes Difuso/complicaciones , Degeneración Cerebelosa Paraneoplásica/sangre , Degeneración Cerebelosa Paraneoplásica/complicaciones , Mieloma Múltiple Quiescente/complicacionesRESUMEN
RATIONALE: Rehabilitation for paraneoplastic cerebellar degeneration (PCD) has been indicated as necessary. However, there are only a few reports on rehabilitation in PCD. We describe the course of physical and cognitive functions and activities of daily living (ADL) in a patient with PCD and examine the effect of rehabilitation, along with a review of relevant literature. PATIENT CONCERNS: A 42-year-old woman experienced rapid deterioration in cerebellar symptoms and was unable to walk. The cerebellar symptoms improved after mastectomy, which was performed 3 months after the onset of symptoms. However, the cerebellar symptoms exacerbated 11 months after the onset of symptoms. She underwent immunotherapy because the level of anti-Yo antibodies was high, and anti-glutamic acid decarboxylase antibodies were detected. DIAGNOSES: She was diagnosed with anti-Yo antibody-positive PCD caused by breast cancer. INTERVENTIONS: Rehabilitation was performed preoperatively, postoperatively, and at 1 year after the onset of symptoms. OUTCOMES: Her physical function and ADL improved after the surgery and at 1 year after the onset of symptoms. Finally, she regained the ability to walk between parallel bars supported with one hand and a walking frame. LESSONS: Given the results of this case and the relevant literature, it appears that rehabilitation improves physical function and ADL after oncotherapy. Particularly, initiating treatment within three months of onset of symptoms may enable patients to walk without assistance.
Asunto(s)
Neoplasias de la Mama/complicaciones , Mastectomía/rehabilitación , Degeneración Cerebelosa Paraneoplásica/rehabilitación , Actividades Cotidianas , Adulto , Autoanticuerpos/sangre , Neoplasias de la Mama/inmunología , Neoplasias de la Mama/rehabilitación , Femenino , Humanos , Degeneración Cerebelosa Paraneoplásica/etiología , Degeneración Cerebelosa Paraneoplásica/inmunología , Resultado del Tratamiento , CaminataRESUMEN
BACKGROUND: Cerebellar degeneration-related protein 2 (CDR2) has been presumed to be the main antigen for the onconeural antibody Yo, which is strongly associated with ovarian cancer and paraneoplastic cerebellar degeneration (PCD). Recent data show that Yo antibodies also target the CDR2-like protein (CDR2L). We, therefore, examined the expression of CDR2 and CDR2L in ovarian cancer tissue from patients with and without Yo antibodies and from various other cancerous and normal human tissues. METHODS: Ovarian cancer tissue and serum samples from 16 patients were included in the study (four with anti-Yo and PCD, two with anti-Yo without PCD, five with only CDR2L antibodies, and five without onconeural antibodies). Clinical data were available for all patients. The human tissues were examined by western blot and immunohistochemistry using rabbit CDR2 and CDR2L antibodies. RESULTS: Ovarian cancers from all 16 patients expressed CDR2 and CDR2L proteins. Both proteins were also present in normal and cancer tissue from mammary tissue, kidney, ovary, prostate, and testis. CONCLUSION: CDR2L is present in ovarian cancers from patients with and without Yo antibodies as was shown previously for CDR2. In addition, both CDR2 and CDR2L proteins are more widely expressed than previously thought, both in normal and cancerous tissues.